• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Virology
  2. Vol 7 (1), 2011
  3. 13-23
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

International Journal of Virology

Year: 2011 | Volume: 7 | Issue: 1 | Page No.: 13-23
DOI: 10.3923/ijv.2011.13.23

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 88

Authors


P.D. Potdar

Country: India

B.S. Daswani

Country: India

N.J. Rane

Country: India

Keywords


  • anti retroviral therapy (ART)
  • highly active antiretroviral therapy (HAART)
  • HIV drug resistance
  • protease
  • reverse transcriptase
Research Article

Drug Resistance Mutations to Protease and Reverse Transcriptase Inhibitors in Treatment Naive HIV-1 Clade C Infected Individuals from Mumbai, India

P.D. Potdar, B.S. Daswani and N.J. Rane
The knowledge of drug resistance mutations in HIV patients is essential for clinicians to decide the optimal Antiretroviral Therapy (ART) combination. Interestingly, most studies reported from India have focused only on mutations in the Reverse Transcriptase (RT) region. Therefore, we carried out a pilot study to identify mutations in both the Protease (PR) and RT regions in treatment naive HIV seropositive patients from Mumbai. The PR and RT regions were successfully amplified and sequenced in fifteen samples using an automated DNA Sequencer. All specimens were identified as Clade C based on pol sequencing. Further, the drug resistance data was interpreted using the online Stanford HIV database. The most prominent mutations found in the RT region were T215 A/G/R (33.3%), Y181C (33.3%) and P225H (33.3%). It is noteworthy that although it is rare to observe major mutations in the PR region in treatment naive HIV patient samples, it was seen that M46L and I47M in >30% of the samples analyzed. Moreover, the homology of these sequences with HIV wild type sequence was verified using National Center for Biotechnology Information (NCBI) blast. Overall, many of the patient samples analyzed had mutations that impart resistance to Indinavir (IDV), Lopinavir (LPV), Nelfinavir (NFV), Stavudine (D4T) and Efavirenz (EFV). Hence, despite the small sample size, the present findings highlight the fact that there may be higher levels of primary HIV drug resistance in Mumbai than previously reported.
PDF Fulltext XML References Citation

How to cite this article

P.D. Potdar, B.S. Daswani and N.J. Rane, 2011. Drug Resistance Mutations to Protease and Reverse Transcriptase Inhibitors in Treatment Naive HIV-1 Clade C Infected Individuals from Mumbai, India. International Journal of Virology, 7: 13-23.

DOI: 10.3923/ijv.2011.13.23

URL: https://scialert.net/abstract/?doi=ijv.2011.13.23

Related Articles

Seroprevalence of HIV Infection in Kwara, Nigeria
Associations Between CD4 Cell Counts and Clinical Presentations Among HIV/AIDS Patients in Cameroon
Hematological Changes in HIV Patients Placed on Anti Retroviral Therapy in Markurdi, Benue State of Nigeria
Evaluation of a New, Highly Sensitive and Specific Primer Set for Reverse-transcriptase PCR Detection of HIV-1 Infected Patients: Comparison with Standard Primers
Association Between Decision Making Autonomy and Knowledge of HIV/AIDS Prevention among ever Married Women in Bangladesh

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved